Building on previous reports that have focused on single syndromes, we report our center’s experience with 18F-flortaucipir in 45 patients representing the clinical spectrum of FTD, MAPT, GRN, and C9ORF72 mutations. This evidence concerns the gene MAPT and frontotemporal dementia.